{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:43:58Z","timestamp":1768545838372,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NIH","award":["R01AR065873"],"award-info":[{"award-number":["R01AR065873"]}]}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.ymgme.2016.03.006","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T06:30:24Z","timestamp":1458282624000},"page":"35-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Salmeterol enhances the cardiac response to gene therapy in Pompe disease"],"prefix":"10.1016","volume":"118","author":[{"given":"Sang-oh","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dwight D.","family":"Koeberl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2016.03.006_bb0005","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2016.03.006_bb0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00455-009-9252-x","article-title":"Oropharyngeal dysphagia in infants and children with infantile Pompe disease","volume":"25","author":"Jones","year":"2009","journal-title":"Dysphagia"},{"key":"10.1016\/j.ymgme.2016.03.006_bb0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3928\/01913913-20100106-08","article-title":"Clinical and histologic ocular findings in pompe disease","volume":"47","author":"Yanovitch","year":"2010","journal-title":"J. Pediatr. Ophthalmol. Strabismus"},{"key":"10.1016\/j.ymgme.2016.03.006_bb0020","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","article-title":"Enzyme replacement therapy in the mouse model of Pompe disease","volume":"80","author":"Raben","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.03.006_bb0025","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ymthe.2004.09.017","article-title":"Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers","volume":"11","author":"Raben","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2016.03.006_bb0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymgme.2011.02.006","article-title":"Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle","volume":"103","author":"Koeberl","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.03.006_bb0035","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ymgme.2011.11.005","article-title":"Beta2 agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease","volume":"105","author":"Koeberl","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.03.006_bb0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1096\/fj.12-207472","article-title":"Adjunctive beta2-agonists reverse neuromuscular involvement in murine Pompe disease","volume":"27","author":"Li","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.ymgme.2016.03.006_bb0045","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.archoralbio.2006.01.003","article-title":"The expressions of insulin-like growth factors, their receptors, and binding proteins are related to the mechanism regulating masseter muscle mass in the rat","volume":"51","author":"Matsumoto","year":"2006","journal-title":"Arch. Oral Biol."},{"key":"10.1016\/j.ymgme.2016.03.006_bb0050","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1465-9921-7-144","article-title":"Hypoxia and dehydroepiandrosterone in old age: a mouse survival study","volume":"7","author":"Debonneuil","year":"2006","journal-title":"Respir. Res."},{"key":"10.1016\/j.ymgme.2016.03.006_bb0055","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1046\/j.1365-2265.1998.00507.x","article-title":"The effect of six months treatment with a 100mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women","volume":"49","author":"Morales","year":"1998","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ymgme.2016.03.006_bb0060","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/hum.2014.115","article-title":"Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade","volume":"26","author":"Han","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2016.03.006_bb0065","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymthe.2004.10.004","article-title":"Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II","volume":"11","author":"Sun","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2016.03.006_bb0070","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/522236","article-title":"Enhanced response to enzyme replacement therapy in pompe disease after the induction of immune tolerance","volume":"81","author":"Sun","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2016.03.006_bb0075","first-page":"45","article-title":"Role of autophagy in the pathogenesis of Pompe disease","volume":"26","author":"Raben","year":"2007","journal-title":"Acta Myol."},{"key":"10.1016\/j.ymgme.2016.03.006_bb0080","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ymgme.2015.09.012","article-title":"A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease","volume":"117","author":"Han","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.03.006_bb0085","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4161\/auto.5.1.7293","article-title":"When more is less: excess and deficiency of autophagy coexist in skeletal muscle in Pompe disease","volume":"5","author":"Raben","year":"2009","journal-title":"Autophagy"},{"key":"10.1016\/j.ymgme.2016.03.006_bb0090","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1096\/fj.13-244202","article-title":"Adjunctive beta2-agonist treatment reduces glycogen independently of receptor-mediated acid alpha-glucosidase uptake in the limb muscles of mice with Pompe disease","volume":"28","author":"Farah","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.ymgme.2016.03.006_bb0095","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1096\/fj.13-241893","article-title":"Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease","volume":"28","author":"Koeberl","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.ymgme.2016.03.006_bb0100","doi-asserted-by":"crossref","first-page":"R1386","DOI":"10.1152\/ajpregu.00324.2002","article-title":"Beta 2-agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol","volume":"283","author":"Ryall","year":"2002","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.ymgme.2016.03.006_bb0105","first-page":"E475","article-title":"Anabolic effects of the beta 2-adrenoceptor agonist salmeterol are dependent on route of administration","volume":"267","author":"Moore","year":"1994","journal-title":"Am. J. Phys."},{"key":"10.1016\/j.ymgme.2016.03.006_bb0110","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/mt.2008.133","article-title":"Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy","volume":"16","author":"Sun","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2016.03.006_bb0115","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ymthe.2005.04.024","article-title":"Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II","volume":"12","author":"Franco","year":"2005","journal-title":"Mol T her."},{"key":"10.1016\/j.ymgme.2016.03.006_bb0120","doi-asserted-by":"crossref","first-page":"11854","DOI":"10.1073\/pnas.182412299","article-title":"Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy","volume":"99","author":"Gao","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2016.03.006_bb0125","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ymthe.2005.01.012","article-title":"Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter","volume":"11","author":"Sun","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2016.03.006_bb0130","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bjp.0706669","article-title":"Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses","volume":"147","author":"Ryall","year":"2006","journal-title":"Br. J. Pharmacol."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719216300257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719216300257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T07:52:03Z","timestamp":1536911523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719216300257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S1096719216300257"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2016.03.006","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Salmeterol enhances the cardiac response to gene therapy in Pompe disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2016.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}